First-in-class, first-in-human phase I results of targeted agents: highlights of the 2008 American society of clinical oncology meeting.
This review summarizes phase I trial results of 11 drugs presented at the American Society of Clinical Oncology meeting held in Chicago IL from May 30 to June 3rd 2008: BMS-663513, CT-322, CVX-045, GDC-0449, GRN163L, LY2181308, PF-00562271, RAV12, RTA 402, XL765, and the survivin vaccine.
Molckovsky
Andrea
A
Division of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, Canada. lim.che.kang@sgh.com.sg
Siu
Lillian L
LL
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents